Show simple item record

dc.contributor.authorMuñoz Manchado, Ana Belén 
dc.contributor.authorVilladiego, Javier
dc.contributor.authorSuárez Luna, Nela
dc.contributor.authorBermejo-Navas, A.
dc.contributor.authorGarrido-Gil, P.
dc.contributor.authorLabandeira-García, J.L.
dc.contributor.authorEchevarría, M.
dc.contributor.authorLópez Barneo, José
dc.contributor.authorToledo Aral, Juan J.
dc.contributor.otherAnatomía Patológica, Biología Celular, Histología, Historia de la Ciencia, Medicina Legal y Forense y Toxicologíaes_ES
dc.date.accessioned2024-09-30T14:24:44Z
dc.date.available2024-09-30T14:24:44Z
dc.date.issued2013
dc.identifier.issn0197-4580
dc.identifier.issn1558-1497
dc.identifier.urihttp://hdl.handle.net/10498/33470
dc.description.abstractIntrastriatal transplantation of dopaminergic carotid body (CB) cells ameliorates parkinsonism in animal models and, with less efficacy, in Parkinson’s disease patients. CB-based cell therapy was initially proposed because of its high dopamine content. However, later studies suggested that its beneficial effect might be due to a trophic action exerted on nigrostriatal neurons. Compatible with this concept are the high levels of neurotrophic factors encountered in CB cells. To test experimentally this idea, unilateral striatal transplants were performed with a sham graft in the contralateral striatum, as a robust internal control. Thereafter, the dopaminergic neurotoxin 1-methyl-4-phenyl- 1,2,3,6, -tetrahydropyridine was injected during 3 months. CB grafts protected from degeneration ipsilateral nigral dopaminergic neurons projecting to the transplant in a dose-dependent manner regarding size and glial cell line-derived neurotrophic factor expression. Grafts performed at different times after the onset of the neurotoxic treatment demonstrated with histological and behavioral methods protection and repair of the nigrostriatal pathway by CB transplants. This study provides a mechanistic explanation for the action of CB transplants on parkinsonian models. It should also help to improve cell therapy approaches to Parkinson’s disease.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceMuñoz-Manchado AB, Villadiego J, Suárez-Luna N, Bermejo-Navas A, Garrido-Gil P, Labandeira-García JL, Echevarría M, López-Barneo J, Toledo-Aral JJ. Neurobiol Aging. 2013 Mar;34(3):902-15. doi: 10.1016/j.neurobiolaging.2012.06.001. Epub 2012 Jun 27.es_ES
dc.titleNeuroprotective and reparative effects of carotid body grafts in a chronic MPTP model of Parkinson’s diseasees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsclosed accesses_ES
dc.identifier.doi10.1016/j.neurobiolaging.2012.06.001
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This work is under a Creative Commons License Attribution-NonCommercial-NoDerivatives 4.0 Internacional